Intestinal Adenocarcinoma

Intestinal adenocarcinoma is a malignant epithelial neoplasm arising from the glandular epithelium of the small intestine, most commonly affecting the duodenum, jejunum, or ileum. It is characterized by uncontrolled proliferation of enterocytes with variable differentiation, often forming glandular structures that invade the intestinal wall and metastasize to regional lymph nodes, liver, and other distant organs. In veterinary medicine, intestinal adenocarcinoma is a significant cause of chronic vomiting, weight loss, and intestinal obstruction in older dogs and cats. The tumor can be classified as well-differentiated, moderately differentiated, or poorly differentiated based on histologic features, and it may present as a solitary mass, annular constriction, or diffuse infiltrative lesion. The disease is locally aggressive, with a high propensity for metastasis, and carries a guarded to poor prognosis depending on stage and completeness of surgical resection.

The exact etiology of intestinal adenocarcinoma in dogs and cats is largely unknown, but several factors are implicated. Genetic mutations, such as alterations in the APC/β-catenin pathway, KRAS, and TP53, have been identified in human colorectal cancer and are suspected in veterinary cases. Chronic inflammation, such as inflammatory bowel disease (IBD), may predispose to neoplastic transformation due to increased cellular turnover and oxidative stress. Dietary factors, including high-fat, low-fiber diets, and exposure to environmental carcinogens (e.g., heterocyclic amines from overcooked meat, nitrosamines) may contribute. In cats, an association with feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) has been suggested but not definitively proven. No specific infectious agent has been consistently isolated. Breed-specific genetic predispositions suggest a hereditary component, particularly in Siamese cats and certain dog breeds like German Shepherds and Boxers.

Intestinal adenocarcinoma is relatively uncommon in dogs and cats, accounting for approximately 10-20% of all intestinal tumors in dogs and up to 50% in cats. It is the most common primary intestinal malignancy in cats, with a mean age of onset around 10-12 years. In dogs, the mean age is 8-10 years. No sex predilection is consistently reported, though some studies suggest a slight male predominance in dogs. Breed predispositions include Siamese cats, and in dogs, German Shepherds, Boxers, and Collies may be at higher risk. The tumor is more frequently located in the duodenum and jejunum in dogs, while cats often present with ileal or jejunal involvement. Geographic variation is not well-documented, but urban environments with higher pollution may increase risk. No seasonal pattern is recognized.

Intestinal adenocarcinoma arises from the intestinal crypt epithelium, where mutations in oncogenes and tumor suppressor genes lead to dysregulated cell proliferation and apoptosis. The tumor initially grows as a polypoid mass or infiltrative lesion within the mucosa, then invades the submucosa, muscularis propria, and serosa. Histologically, neoplastic cells form acinar or tubular structures, often with desmoplastic stroma. As the tumor grows, it can cause partial or complete intestinal obstruction, leading to proximal bowel dilation, stasis, and malabsorption. Ulceration of the tumor surface can result in chronic blood loss and anemia. Invasion into lymphatic and blood vessels facilitates metastasis to regional lymph nodes (mesenteric), liver, lungs, and occasionally other organs. Paraneoplastic syndromes, such as cachexia and anemia of chronic disease, may occur due to cytokine release (e.g., TNF-α, IL-6). The desmoplastic reaction can cause annular constriction, leading to stricture and obstruction. Systemic effects include weight loss, hypoalbuminemia due to protein-losing enteropathy, and electrolyte imbalances from chronic vomiting and diarrhea.

Predisposing factors for intestinal adenocarcinoma include advanced age (older than 8 years), chronic inflammatory bowel disease (IBD), and possibly dietary factors such as high consumption of red meat or processed foods. Genetic predisposition is evident in certain breeds, suggesting inherited mutations. Immunosuppression, whether from chronic disease or drug therapy, may increase susceptibility. Environmental carcinogens, including tobacco smoke and industrial pollutants, may play a role. In cats, chronic gastrointestinal inflammation and possibly viral infections (FeLV, FIV) are risk factors. Obesity and sedentary lifestyle may indirectly increase risk through chronic inflammation. Additionally, previous radiation exposure to the abdomen is a rare but recognized risk factor.

Clinical signs of intestinal adenocarcinoma are often insidious and progressive. In dogs, chronic vomiting, weight loss, and decreased appetite are common. Cats may present with vomiting, diarrhea, and weight loss, sometimes with palpable abdominal mass. Signs of intestinal obstruction include abdominal pain, distension, and tenesmus. Melena or hematochezia may occur if the tumor ulcerates. Anemia can cause lethargy and pale mucous membranes. In advanced cases, ascites may develop due to peritoneal carcinomatosis or hypoalbuminemia. Physical examination may reveal a palpable abdominal mass, thickened bowel loops, or evidence of weight loss. Paraneoplastic hypercalcemia has been reported in some cases, leading to polyuria and polydipsia. Systemic signs such as fever and lethargy may occur with secondary infection or tumor necrosis.

Differential diagnoses for intestinal adenocarcinoma include: 1) Lymphoma (especially in cats) – distinguished by diffuse thickening, cytology/histopathology showing lymphocytic infiltration, and immunophenotyping. 2) Inflammatory bowel disease (IBD) – chronic inflammation without neoplastic cells on biopsy, responds to immunosuppressive therapy. 3) Other intestinal tumors: leiomyosarcoma, gastrointestinal stromal tumor (GIST), carcinoid – differentiated by histopathology and immunohistochemistry (e.g., c-KIT, smooth muscle actin). 4) Intestinal foreign body – acute onset, imaging shows obstruction, surgical exploration reveals foreign material. 5) Intussusception – often acute, ultrasound shows 'target sign', reducible or surgical. 6) Fungal or bacterial enteritis (e.g., histoplasmosis, pythiosis) – endemic areas, cytology/histopathology with organisms. 7) Parasitic infection (e.g., hookworms) – fecal examination, response to anthelmintics. 8) Chronic pancreatitis – elevated pancreatic lipase, imaging of pancreas. 9) Protein-losing enteropathy (e.g., lymphangiectasia) – hypoalbuminemia, intestinal biopsy. 10) Systemic diseases like renal failure or hyperthyroidism (cats) – blood work and hormone levels.

The diagnostic approach begins with a thorough history and physical examination, including abdominal palpation. Initial laboratory tests include complete blood count (CBC), serum biochemistry profile, urinalysis, and fecal examination. If intestinal disease is suspected, abdominal radiographs may reveal an obstructive pattern, mass effect, or loss of serosal detail. Abdominal ultrasound is the next step, allowing evaluation of intestinal wall thickness, layering, and identification of masses or lymphadenopathy. If a mass is identified, fine-needle aspiration (FNA) may be performed for cytology, but definitive diagnosis requires biopsy via endoscopy or surgery. Endoscopic biopsy is less invasive but may miss deeper lesions; surgical full-thickness biopsy is preferred for accurate histologic grading and staging. Staging includes thoracic radiographs to rule out pulmonary metastasis and abdominal ultrasound for liver or lymph node involvement. Advanced imaging like CT or MRI may be used for surgical planning. Histopathology with immunohistochemistry (e.g., cytokeratin, vimentin, c-KIT) confirms the diagnosis and differentiates from other tumors. If hypercalcemia is present, parathyroid hormone-related protein (PTHrP) levels may be measured.

Hematology may show non-regenerative anemia due to chronic blood loss or anemia of chronic disease. Leukocytosis may occur with inflammation or infection. Serum biochemistry may reveal hypoalbuminemia due to protein-losing enteropathy, elevated liver enzymes (ALP, ALT) if metastasis to liver, and electrolyte imbalances (hypokalemia, hyponatremia) from vomiting and diarrhea. Hypercalcemia may be present in some cases. Urinalysis is usually unremarkable but may show low urine specific gravity if hypercalcemia causes renal concentrating defect. Blood gas analysis may indicate metabolic acidosis or alkalosis depending on vomiting severity. Specific biomarkers: C-reactive protein (CRP) may be elevated as a nonspecific inflammatory marker. Fecal occult blood test may be positive. In cats, feline pancreatic lipase immunoreactivity (fPLI) may be normal unless concurrent pancreatitis. Serum cobalamin and folate levels may be altered due to intestinal malabsorption. Serology/PCR for infectious agents (e.g., FeLV, FIV) may be performed in cats.

Radiography: Abdominal radiographs may show a soft tissue mass, intestinal obstruction with dilated loops proximal to the mass, or loss of serosal detail due to peritonitis. Thoracic radiographs are essential to detect pulmonary metastases. Ultrasonography: The most valuable imaging modality. Findings include focal or diffuse thickening of the intestinal wall with loss of normal layering, a hypoechoic mass, or an annular constricting lesion. Regional lymphadenopathy (mesenteric lymph nodes) may be seen. Doppler ultrasound can assess vascular invasion. Computed Tomography (CT): Provides detailed cross-sectional images, useful for surgical planning and staging, especially for detecting small metastases in liver or lungs. Magnetic Resonance Imaging (MRI): Rarely used but can delineate soft tissue extension. Endoscopy: Allows direct visualization of the mucosal surface and biopsy collection, but may miss submucosal or serosal lesions. Fluoroscopy: Barium contrast studies can reveal filling defects or strictures, but are less commonly used now with ultrasound availability. Echocardiography: Not directly relevant, but may be performed if cardiac disease is suspected as a comorbidity.

Cytology from FNA of an intestinal mass may show clusters of epithelial cells with anisocytosis, anisokaryosis, and prominent nucleoli, but cytology is often nondiagnostic due to desmoplasia. Histopathology is the gold standard. Full-thickness biopsy reveals neoplastic cells forming acini or tubules, often with mucin secretion. The tumor is graded based on differentiation: well-differentiated (glandular structures well-formed), moderately differentiated, and poorly differentiated (solid sheets of cells). Invasion into the intestinal wall layers (mucosa, submucosa, muscularis, serosa) is assessed. Lymphovascular invasion is a negative prognostic indicator. Special stains: Periodic acid-Schiff (PAS) for mucin, Alcian blue for acidic mucins, and immunohistochemistry for cytokeratin (epithelial origin), vimentin (mesenchymal), and c-KIT (to rule out GIST). Ki-67 proliferation index may correlate with aggressiveness.

Treatment of intestinal adenocarcinoma is primarily surgical resection. The goal is complete excision (R0) with wide margins (at least 2-3 cm) and removal of affected lymph nodes. In dogs, segmental resection and anastomosis is the standard. In cats, the same approach is used. If the tumor is non-resectable or metastatic, palliative options include chemotherapy (e.g., doxorubicin, carboplatin) and supportive care. However, the response to chemotherapy is generally poor. Adjuvant chemotherapy may be considered for high-grade tumors or incomplete margins, but evidence is limited. Supportive care includes fluid therapy for dehydration and electrolyte imbalances, antiemetics (e.g., maropitant 1 mg/kg IV/SC q24h), and nutritional support (e.g., feeding tubes). Pain management with opioids (e.g., buprenorphine 0.01-0.02 mg/kg IV/SC q8-12h) is essential postoperatively. In cases of intestinal obstruction, emergency surgery is indicated. For inoperable cases, medical management with corticosteroids (e.g., prednisone 1 mg/kg PO q24h) may provide temporary symptomatic relief but does not alter survival.

The prognosis for intestinal adenocarcinoma is guarded to poor. In dogs, median survival time (MST) after surgical resection is approximately 10-15 months, with 1-year survival rates around 50%. In cats, MST is shorter, around 6-12 months. Negative prognostic factors include incomplete surgical margins, lymph node metastasis, high histologic grade, and presence of clinical signs at diagnosis. Cats with intestinal adenocarcinoma have a higher rate of metastasis at diagnosis (up to 50%). Without surgery, survival is typically less than 1-2 months. Response to chemotherapy is poor, with overall response rates below 20%. Early detection and complete resection offer the best chance for prolonged survival, but recurrence is common.

Post-treatment follow-up is crucial. Recheck examinations should be performed every 1-3 months for the first year, then every 3-6 months thereafter. Each visit should include a physical examination, body weight, and abdominal palpation. Serial abdominal ultrasound is recommended every 3-6 months to monitor for local recurrence or metastasis. Thoracic radiographs should be repeated every 3-6 months to detect pulmonary metastases. Blood work (CBC, biochemistry) should be performed at each recheck to monitor for anemia, hypoalbuminemia, or organ dysfunction. If chemotherapy is administered, CBC should be checked before each dose to monitor for myelosuppression. Owners should be educated on signs of recurrence, such as vomiting, diarrhea, weight loss, or abdominal distension, and advised to seek immediate veterinary attention. Nutritional counseling and supportive care should be continued as needed.

Pearls: 1) Always consider intestinal adenocarcinoma in older cats with chronic vomiting and weight loss, even if abdominal palpation is unremarkable. 2) Ultrasound is highly sensitive for detecting intestinal masses; loss of layering is a key feature. 3) Surgical biopsy is superior to endoscopic biopsy for definitive diagnosis and staging. 4) Complete surgical excision with wide margins is the most important prognostic factor. 5) In cats, intestinal adenocarcinoma often metastasizes early, so thoracic radiographs and abdominal ultrasound are essential for staging. Pitfalls: 1) Do not rely solely on cytology; it often yields false negatives due to desmoplasia. 2) Avoid delaying surgery in cases of intestinal obstruction; emergency surgery is life-saving. 3) Do not assume that a palpable abdominal mass is lymphoma; adenocarcinoma is common in cats. 4) Be cautious with corticosteroid use before biopsy, as it can alter histologic appearance. 5) Do not overlook hypercalcemia; it may be paraneoplastic and requires management.

Chemotherapy protocols for intestinal adenocarcinoma are not standardized, but based on Plumb's Veterinary Drug Handbook, the following may be considered: Doxorubicin: Dogs: 30 mg/m² IV every 3 weeks; Cats: 1 mg/kg IV every 3 weeks (or 20 mg/m²). Carboplatin: Dogs: 300 mg/m² IV every 3 weeks; Cats: 200-240 mg/m² IV every 3 weeks. These drugs require cardiac monitoring (echocardiogram) for doxorubicin and renal function assessment for carboplatin. Supportive medications: Maropitant (Cerenia): 1 mg/kg IV/SC q24h for vomiting. Ondansetron: 0.5-1 mg/kg IV q12h. Metoclopramide: 1-2 mg/kg/day as CRI for refractory vomiting. For pain: Buprenorphine: 0.01-0.02 mg/kg IV/SC q8-12h. For gastric protection: Omeprazole: 1 mg/kg PO q12h. For nutritional support: Mirtazapine: 3.75 mg/cat PO q48h as appetite stimulant. Antibiotics are not routinely indicated unless there is evidence of bacterial translocation or infection. All dosages should be adjusted for renal or hepatic impairment. Contraindications: Doxorubicin is contraindicated in animals with pre-existing cardiac disease; carboplatin should be avoided in animals with renal insufficiency.

Evidence-based literature on intestinal adenocarcinoma in dogs and cats is limited to retrospective studies and case series. A landmark study by Patnaik et al. (1976) described the histologic classification and biologic behavior of intestinal neoplasms in dogs. More recent studies, such as that by Rissetto et al. (2011), reported that surgical resection in dogs with intestinal adenocarcinoma resulted in a median survival of 15 months, with incomplete margins and lymph node metastasis being negative prognostic factors. In cats, a study by Slawienski et al. (1997) found a median survival of 6 months after surgery, with a high rate of metastasis. Chemotherapy has not been shown to significantly improve survival in either species. ACVIM consensus guidelines on gastrointestinal tumors recommend surgical resection as the primary treatment, with chemotherapy considered for high-grade or metastatic disease, though evidence is weak. There is ongoing research into targeted therapies, such as tyrosine kinase inhibitors (e.g., toceranib), but data are preliminary. Overall, the literature emphasizes the importance of early diagnosis and complete surgical excision.